The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas

por Ball, Mark W., Gorin, Michael A., Drake, Charles G., Hammers, Hans J., Allaf, Mohamad E.
Publicado en Eur Urol Focus (2017)

Detection of (18)F-FDG PET/CT Occult Lesions with (18)F-DCFPyL PET/CT in a Patient with Metastatic Renal Cell Carcinoma

por Rowe, Steven P., Gorin, Michael A., Hammers, Hans J., Pomper, Martin G., Allaf, Mohamad E., Javadi, M. Som
Publicado en Clin Nucl Med (2016)

Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (18)F-DCFPyL PET/CT

por Rowe, Steven P., Gorin, Michael A., Hammers, Hans J., Javadi, M. Som, Hawasli, Hazem, Szabo, Zsolt, Cho, Steve Y., Pomper, Martin G., Allaf, Mohamad E.
Publicado en Ann Nucl Med (2015)

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study

por Ball, Mark W., Gorin, Michael A., Guner, Gunes, Pierorazio, Phillip M., Netto, George, Paller, Channing J., Hammers, Hans J., Diaz, Luis A., Allaf, Mohamad E.
Publicado en Clin Genitourin Cancer (2016)

Screening assay for blood vessel maturation inhibitors

por Fu, Chenglai, van der Zwan, Anita, Gerber, Stephanie, Van Den Berg, Susan, No, Elisa, Wang, Wayne C.H., Sheibani, Nader, Carducci, Michael A., Kachhap, Sushant, Hammers, Hans J.
Publicado 2013

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial

por George, Saby, Motzer, Robert J., Hammers, Hans J., Redman, Bruce G., Kuzel, Timothy M., Tykodi, Scott S., Plimack, Elizabeth R., Jiang, Joel, Waxman, Ian M., Rini, Brian I.
Publicado en JAMA Oncol (2016)

Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database

por Singla, Nirmish, Hutchinson, Ryan C., Ghandour, Rashed A., Freifeld, Yuval, Fang, Dong, Sagalowsky, Arthur I., Lotan, Yair, Bagrodia, Aditya, Margulis, Vitaly, Hammers, Hans J., Woldu, Solomon L.
Publicado en Urol Oncol (2020)

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma

por Bergerot, Cristiane Decat, Battle, Dena, Bergerot, Paulo Gustavo, Dizman, Nazli, Jonasch, Eric, Hammers, Hans J., George, Daniel J., Bex, Axel, Ljungberg, Borje, Pal, Sumanta Kumar, Staehler, Michael D.
Publicado en Front Oncol (2019)

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

por Cella, David, Grünwald, Viktor, Escudier, Bernard, Hammers, Hans J, George, Saby, Nathan, Paul, Grimm, Marc-Oliver, Rini, Brian I, Doan, Justin, Ivanescu, Cristina, Paty, Jean, Mekan, Sabeen, Motzer, Robert J
Publicado en Lancet Oncol (2019)

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

por Hammers, Hans J, Verheul, Henk M, Salumbides, Brenda, Sharma, Rajni, Rudek, Michelle, Jaspers, Janneke, Shah, Preeti, Ellis, Leigh, Shen, Li, Paesante, Silvia, Dykema, Karl, Furge, Kyle, Teh, Bin T, Netto, George, Pili, Roberto
Publicado 2010

Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors

por Gul, Anita, Stewart, Tyler F., Mantia, Charlene M., Shah, Neil J., Gatof, Emily Stern, Long, Ying, Allman, Kimberly D., Ornstein, Moshe C., Hammers, Hans J., McDermott, David F., Atkins, Michael B., Hurwitz, Michael, Rini, Brian I.
Publicado en J Clin Oncol (2020)

Immunomodulation by entinostat in renal cell carcinoma patients receiving high dose interleukin 2: a multicenter, single-arm, phase 1/2 trial (NCI-CTEP#7870)

por Pili, Roberto, Quinn, David I., Hammers, Hans J., Monk, Paul, George, Saby, Dorff, Tanya B., Olencki, Thomas, Shen, Li, Orillion, Ashley, Lamonica, Dominick, Fragomeni, Roberto S., Szabo, Zsolt, Hutson, Alan, Groman, Adrienne, Perkins, Susan M., Piekarz, Richard, Carducci, Michael A.
Publicado en Clin Cancer Res (2017)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

por Amin, Asim, Plimack, Elizabeth R, Ernstoff, Marc S, Lewis, Lionel D, Bauer, Todd M, McDermott, David F, Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I, Heng, Daniel Y C, Knox, Jennifer, Voss, Martin H, Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J
Publicado en J Immunother Cancer (2018)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

por Amin, Asim, Plimack, Elizabeth R., Ernstoff, Marc S., Lewis, Lionel D., Bauer, Todd M., McDermott, David F., Carducci, Michael, Kollmannsberger, Christian, Rini, Brian I., Heng, Daniel Y. C., Knox, Jennifer, Voss, Martin H., Spratlin, Jennifer, Berghorn, Elmer, Yang, Lingfeng, Hammers, Hans J.
Publicado en J Immunother Cancer (2019)

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

por Motzer, Robert J., Rini, Brian I., McDermott, David F., Redman, Bruce G., Kuzel, Timothy M., Harrison, Michael R., Vaishampayan, Ulka N., Drabkin, Harry A., George, Saby, Logan, Theodore F., Margolin, Kim A., Plimack, Elizabeth R., Lambert, Alexandre M., Waxman, Ian M., Hammers, Hans J.
Publicado en J Clin Oncol (2015)

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

por Naidoo, Jarushka, Cappelli, Laura C., Forde, Patrick M., Marrone, Kristen A., Lipson, Evan J., Hammers, Hans J., Sharfman, William H., Le, Dung T., Baer, Alan N., Shah, Ami A., Albayda, Jemima, Manno, Rebecca L., Haque, Uzma, Gutierrez, Anna Kristina, Bingham, Clifton O., Brahmer, Julie R.
Publicado en Oncologist (2017)

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

por Hammers, Hans J., Plimack, Elizabeth R., Infante, Jeffrey R., Rini, Brian I., McDermott, David F., Lewis, Lionel D., Voss, Martin H., Sharma, Padmanee, Pal, Sumanta K., Razak, Albiruni R. Abdul, Kollmannsberger, Christian, Heng, Daniel Y.C., Spratlin, Jennifer, McHenry, M. Brent, Amin, Asim
Publicado en J Clin Oncol (2017)

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

por Choueiri, Toni K, Atkins, Michael B, Bakouny, Ziad, Carlo, Maria I, Drake, Charles G, Jonasch, Eric, Kapur, Payal, Lewis, Bryan, Linehan, W Marston, Mitchell, Michael J, Pal, Sumanta K, Pels, Kevin, Poteat, Susan, Rathmell, W Kimryn, Rini, Brian I, Signoretti, Sabina, Tannir, Nizar, Uzzo, Robert, Wood, Christopher G, Hammers, Hans J
Publicado en J Natl Cancer Inst (2020)

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

por Cella, David, Escudier, Bernard, Tannir, Nizar M., Powles, Thomas, Donskov, Frede, Peltola, Katriina, Schmidinger, Manuela, Heng, Daniel Y.C., Mainwaring, Paul N., Hammers, Hans J., Lee, Jae Lyun, Roth, Bruce J., Marteau, Florence, Williams, Paul, Baer, John, Mangeshkar, Milan, Scheffold, Christian, Hutson, Thomas E., Pal, Sumanta, Motzer, Robert J., Choueiri, Toni K.
Publicado en J Clin Oncol (2018)

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

por McDermott, David F., Drake, Charles G., Sznol, Mario, Choueiri, Toni K., Powderly, John D., Smith, David C., Brahmer, Julie R., Carvajal, Richard D., Hammers, Hans J., Puzanov, Igor, Hodi, F. Stephen, Kluger, Harriet M., Topalian, Suzanne L., Pardoll, Drew M., Wigginton, Jon M., Kollia, Georgia D., Gupta, Ashok, McDonald, Dan, Sankar, Vindira, Sosman, Jeffrey A., Atkins, Michael B.
Publicado en J Clin Oncol (2015)